[{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||Adrenergic alpha-A1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||5-hydroxytryptamine receptor 1A","graph1":"Urology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||M2 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Adalvo \/ Adamed Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adamed Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Tamsulosin HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide-Based Therapeutics Summit
Not Confirmed
Peptide-Based Therapeutics Summit
Not Confirmed

Details : DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 15, 2023

Lead Product(s) : Tamsulosin,Tadalafil

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

Peptide-Based Therapeutics Summit
Not Confirmed
Peptide-Based Therapeutics Summit
Not Confirmed

Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.

Product Name : Vesomni-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 23, 2023

Lead Product(s) : Solifenacin Succinate,Tamsulosin

Therapeutic Area : Urology

Highest Development Status : Approved FDF

Sponsor : Adamed Pharma

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

Peptide-Based Therapeutics Summit
Not Confirmed
Peptide-Based Therapeutics Summit
Not Confirmed

Details : Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 12, 2022

Lead Product(s) : Tamsulosin,Solifenacin Succinate

Therapeutic Area : Urology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank